Veldoreotide - Strongbridge Biopharma
Alternative Names: COR-005; DG-3173; PTR-3173; Somatoprim; Veldoreotide extended release; VeldotideLatest Information Update: 28 Sep 2022
At a glance
- Originator Peptor
- Developer Strongbridge Biopharma
- Class Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies
- Mechanism of Action Somatostatin receptor 2 agonists; Somatostatin receptor 5 agonists; Somatostatin receptor subtype 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acromegaly
- No development reported Adrenal cortical hyperfunction; Diabetic retinopathy; Neuroendocrine tumours
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Acromegaly in USA (Controlled release)
- 05 Oct 2021 Strongbridge Biopharma and Xeris Pharmaceuticals has been acquired by Xeris Biopharma Holdings
- 23 May 2021 Strongbridge Biopharma has six pending patent applications for veldoreotide in China, Japan, Canada and various countries in Europe